Date: 2017-12-11
Type of information: Private placement
Company: Viking Therapeutics (USA - PA)
Investors:
Amount: $14.8 million
Funding type: private placement
Planned used:
- Viking Therapeutics currently intends to use the net proceeds from the offering for continued development of its VK5211, VK2809 and VK0214 programs and for general research and development, working capital and general corporate purposes.
- VK5211 is a novel, orally available, non-steroidal selective androgen receptor modulator (SARM), in Phase 2 development for the treatment of patients recovering from non-elective hip fracture surgery. VK5211 belongs to a family of novel non-steroidal SARM compounds based on tissue-specific gene expression and other functional, cell-based technologies. In Phase 1 clinical trials, VK5211 demonstrated statistically significant increases in lean body mass among treated subjects following 21 days of treatment.
- VK2809 and VK0214, are novel, orally available, selective thyroid hormone receptor beta (TR?) agonists for lipid disorders.
Others:
- • On December 11, 2017, Viking Therapeutics announced the closing of its previously announced underwritten public offering of 5,900,000 shares of its common stock, including 769,565 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares to cover over-allotments, at a public offering price of $2.50 per share, before deducting underwriting discounts and commissions and estimated offering expenses payable by Viking. The gross proceeds to Viking from this offering are approximately $14.8 million, before deducting underwriting discounts and commissions and other estimated offering expenses. pment, working capital and general corporate purposes.
- William Blair & Company, L.L.C. acted as sole book-running manager for the offering and Maxim Group LLC and Roth Capital Partners acted as co-managers for the offering.
Therapeutic area: Endocrinological diseases - Metabolic diseases
Is general: Yes
